• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    6/5/24 8:06:43 AM ET
    $AGEN
    $BRNS
    $CCM
    $CMPS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGEN alert in real time by email

    Gainers

    • ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 71.6% to $0.15 during Wednesday's pre-market session. The company's market cap stands at $1.5 million.
    • Concord Medical Services (NYSE:CCM) stock moved upwards by 29.04% to $2.71. The company's market cap stands at $117.6 million.
    • Barinthus Biotherapeutics (NASDAQ:BRNS) shares increased by 21.69% to $2.3. The market value of their outstanding shares is at $89.7 million.
    • Heart Test Laboratories (NASDAQ:HSCS) stock moved upwards by 12.87% to $5.81. The company's market cap stands at $3.8 million.
    • I-MAB (NASDAQ:IMAB) shares increased by 12.23% to $2.11. The company's market cap stands at $170.6 million.
    • Agenus (NASDAQ:AGEN) stock rose 11.54% to $19.52. The company's market cap stands at $409.9 million.

    Losers

    • SILO Pharma (NASDAQ:SILO) shares declined by 34.7% to $1.47 during Wednesday's pre-market session. The company's market cap stands at $4.1 million.
    • Cue Health (NASDAQ:HLTH) stock decreased by 25.57% to $0.05. The company's market cap stands at $7.3 million.
    • Fresh2 Group (NASDAQ:FRES) stock decreased by 20.52% to $0.35. The market value of their outstanding shares is at $8.6 million.
    • ThermoGenesis Holdings (NASDAQ:THMO) stock fell 13.31% to $0.55. The market value of their outstanding shares is at $4.4 million.
    • Compass Pathways (NASDAQ:CMPS) shares decreased by 13.3% to $6.65. The company's market cap stands at $454.7 million.
    • Marker Therapeutics (NASDAQ:MRKR) stock fell 12.09% to $3.2. The market value of their outstanding shares is at $28.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGEN
    $BRNS
    $CCM
    $CMPS

    CompanyDatePrice TargetRatingAnalyst
    COMPASS Pathways Plc
    $CMPS
    12/10/2025$15.00Perform → Outperform
    Oppenheimer
    I-MAB
    $IMAB
    10/3/2025$9.00Outperform
    Leerink Partners
    I-MAB
    $IMAB
    9/9/2025$7.00Buy
    BTIG Research
    COMPASS Pathways Plc
    $CMPS
    6/23/2025$11.00 → $6.00Outperform → In-line
    Evercore ISI
    Agenus Inc.
    $AGEN
    6/4/2025$25.00Neutral → Buy
    H.C. Wainwright
    Marker Therapeutics Inc.
    $MRKR
    3/5/2025$8.00Buy
    Canaccord Genuity
    COMPASS Pathways Plc
    $CMPS
    2/27/2025$11.00Buy
    Stifel
    COMPASS Pathways Plc
    $CMPS
    7/23/2024$23.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $AGEN
    $BRNS
    $CCM
    $CMPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Yang Jianyu

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:54 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by Concord Medical Services Holdings Limited

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:33 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by Concord Medical Services Holdings Limited

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:12 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    $AGEN
    $BRNS
    $CCM
    $CMPS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $735 worth of shares (2,000 units at $0.37), increasing direct ownership by 0.95% to 211,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/21/25 6:35:50 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $4,847 worth of shares (12,000 units at $0.40), increasing direct ownership by 6% to 209,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/20/25 4:00:32 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $AGEN
    $BRNS
    $CCM
    $CMPS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AGEN
    $BRNS
    $CCM
    $CMPS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

    Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer Strengthened manufacturing capabilities through collaboration with Cellipont Bioservices and expanded Board of Directors with appointment of Kathryn Penkus Corzo HOUSTON, March 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, today a

    3/18/26 5:31:30 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

    A novel, chemo-sparing strategy (BBoPCO): introducing BOT+BAL in 1L MSS mCRC to extend survival and reduce use of cytotoxic chemotherapy Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that preliminary results from an investigator-sponsored study evaluating botensilimab (BOT) in combination with balstilimab (BAL) in first-line microsatellite stable colorectal cancer (MSS CRC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 18–23 in San Diego, CA. The BBoPCO study (Botensilimab and Balstilimab Optimization in Colorectal Cancer; NCT06268015) is the first trial of its kind to advance a combination im

    3/17/26 4:40:00 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

    Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today reported financial results for its fiscal third quarter ended January 31, 2026 ("FQ3 2026") and provided a business update. Third Quarter and Recent Highlights During the third quarter and subsequent period, the Company continued advancing the commercialization of its MyoVista Insights™ healthcare IT platform and submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administra

    3/16/26 4:15:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    $AGEN
    $BRNS
    $CCM
    $CMPS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    COMPASS Pathways upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded COMPASS Pathways from Perform to Outperform and set a new price target of $15.00

    12/10/25 8:10:44 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on I-Mab with a new price target

    Leerink Partners initiated coverage of I-Mab with a rating of Outperform and set a new price target of $9.00

    10/3/25 8:40:32 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on I-Mab with a new price target

    BTIG Research initiated coverage of I-Mab with a rating of Buy and set a new price target of $7.00

    9/9/25 7:57:49 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGEN
    $BRNS
    $CCM
    $CMPS
    SEC Filings

    View All

    SEC Form 10-K filed by Marker Therapeutics Inc.

    10-K - Marker Therapeutics, Inc. (0001094038) (Filer)

    3/18/26 5:26:35 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by HeartSciences Inc.

    DEF 14A - HeartSciences Inc. (0001468492) (Filer)

    3/17/26 4:16:35 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form 10-K filed by Agenus Inc.

    10-K - AGENUS INC (0001098972) (Filer)

    3/16/26 5:19:19 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    $BRNS
    $CCM
    $CMPS
    Leadership Updates

    Live Leadership Updates

    View All

    Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

    Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer Strengthened manufacturing capabilities through collaboration with Cellipont Bioservices and expanded Board of Directors with appointment of Kathryn Penkus Corzo HOUSTON, March 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, today a

    3/18/26 5:31:30 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

    Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel (AAC) program. BOT is an Fc-enhanced multifunctional CTLA-4 antibody and BAL is a PD-1 antibody. In combination, BOT/BAL is being investigated in patients with microsatellite-stable colorectal cancer (MSS CRC), a population that has hi

    11/18/25 8:41:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

    HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company's Board of Directors, effective November 1, 2025. Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent board director with more than 30 years of global leadership spanning R&D, clinical trials, regulatory approvals, commercialization, and corporate strategy across multiple therapeutic modalities and in

    11/5/25 7:30:00 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGEN
    $BRNS
    $CCM
    $CMPS
    Financials

    Live finance-specific insights

    View All

    Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

    Early access programs expand globally: 200+ physician inquiries across 30+ countries; $4.2M in initial program revenue recognized CRC leads BOT+BAL clinical development: 42% two-year overall survival and ~21-month median overall survival in heavily pretreated microsatellite stable (MSS) metastatic CRC (mCRC) patients BATTMAN Phase 3 registrational trial underway: First global next-generation CTLA-4/PD-1 combination registrational trial in refractory MSS mCRC France expands reimbursed AAC access: Metastatic ovarian cancer and sarcoma added alongside MSS mCRC Zydus collaboration strengthens balance sheet and manufacturing capacity: Strategic capital and dedicated U.S. biologics p

    3/16/26 7:30:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments

    Proposed combination with Clywedog Therapeutics Inc. ("Clywedog") to create a differentiated company focusing on clinical metabolic and autoimmune pipeline assets and to build on the Company's base of high caliber institutional investors, expected to complete in the second quarter of 2026Multiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026 GERMANTOWN, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), today announced its financial results for the year ended December 31, 2025, and provided an overview of the Company's co

    3/13/26 8:00:00 AM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

    France grants reimbursed access with patients having commenced treatment Two-year BOT/BAL survival presented at ESMO spanning more than five cancers in over 400 patients Phase 3 on track to commence in fourth quarter 2025 Agenus Inc. (NASDAQ:AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate access (AAC) in France for botensilimab plus balstilimab (BOT/BAL), new survival data presented at ESMO and ESMO‑GI across more than 400 patients spanning more than five refractory cancers, and initiation of the global Phase 3 BATTMAN trial. Access & Regulatory Franc

    11/10/25 7:30:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    $BRNS
    $CCM
    $CMPS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agenus Inc.

    SC 13G/A - AGENUS INC (0001098972) (Subject)

    11/14/24 7:58:18 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

    SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

    11/14/24 4:35:16 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

    SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

    11/14/24 4:20:24 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care